Literature DB >> 21630072

The role of hemoglobin variant replacement in retinopathy of prematurity.

Wojciech Podraza1, Hanna Podraza, Karolina Jezierska, Joanna Szwed, Monika Modrzejewska, Jacek Rudnicki, Agnieszka Kordek, Hanna Domek.   

Abstract

OBJECTIVE: To conduct tests of relationships between different factors that could influence the course of retinopathy of prematurity (ROP) and ROP, particularly the role of hemoglobin variant replacement in adult blood transfusions.
METHODS: A retrospective, observational study of 83 infants born between 23 and 34 wks gestation was conducted.
RESULTS: The infants without ROP, with 1 and 2 stage of ROP and with ≥ 3 stage of ROP received Q 28 (12-134); 51 (14-149); 156 (38-244) ml/kg of transfused blood, respectively, and the factor Qt was 1,545 (560-10,045); 3,093 (614-13,419); 11,907 (1,288-20,638) (ml/kg)·day, respectively. For the same groups MCV(35) (mean cell volume at the arbitrary time of the 35(th) wk post-conception) was 92.3 (82.9-110.5); 91.0 (79.3-101.4); 87.1 (80.2-94.8) fl, respectively, and factor P(MCV)/t was 99.5 (89.2-108.8); 96.3 (84.6-106.3); 90.7 (85.3-96.5) fl, respectively. There is high influence on the stage of ROP of the amount of transfused blood and MCV, both with or without the time factor. The statistical differences between P(MCV)/t were more significant than the differences between MCV(35), for different stages of ROP.
CONCLUSIONS: The influence of the time factor on the statistical differences of MCV but not on the amount of transfused adult blood suggests that HbF - HbA replacement may play a role in ROP development.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21630072     DOI: 10.1007/s12098-011-0460-7

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  20 in total

Review 1.  Data-driven blood banking practices for neonatal RBC transfusions.

Authors:  R G Strauss
Journal:  Transfusion       Date:  2000-12       Impact factor: 3.157

Review 2.  Neonatal red blood cell transfusions.

Authors:  N L C Luban
Journal:  Vox Sang       Date:  2004-07       Impact factor: 2.144

3.  Severe retinopathy of prematurity in infants <30 weeks' gestation in New South Wales and the Australian Capital Territory from 1992 to 2002.

Authors:  D A Todd; A Wright; J Smith
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-01-24       Impact factor: 5.747

4.  Retinopathy of prematurity in small-for-gestational age infants compared with those of appropriate size for gestational age.

Authors:  C A Dhaliwal; B W Fleck; E Wright; C Graham; N McIntosh
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2008-09-11       Impact factor: 5.747

5.  Incidence of retinopathy of prematurity in Lothian, Scotland, from 1990 to 2004.

Authors:  C Dhaliwal; B Fleck; E Wright; C Graham; N McIntosh
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2008-05-07       Impact factor: 5.747

6.  Risk factors associated with retinopathy of prematurity (ROP) in northern Jutland, Denmark 1990-1993.

Authors:  H Nødgaard; H Andreasen; H Hansen; H T Sørensen
Journal:  Acta Ophthalmol Scand       Date:  1996-06

Review 7.  Oxidative stress in the newborn--a 30-year perspective.

Authors:  Ola Didrik Saugstad
Journal:  Biol Neonate       Date:  2005

8.  An international classification of retinopathy of prematurity. The Committee for the Classification of Retinopathy of Prematurity.

Authors: 
Journal:  Arch Ophthalmol       Date:  1984-08

9.  The effect of blood transfusion on the hemoglobin oxygen dissociation curve of very early preterm infants during the first week of life.

Authors:  Virginie De Halleux; Anita Truttmann; Carmen Gagnon; Harry Bard
Journal:  Semin Perinatol       Date:  2002-12       Impact factor: 3.300

10.  Late postnatal systemic steroids predispose to retinopathy of prematurity in very-low-birth-weight infants: a comparative study.

Authors:  Tatiana Smolkin; Maya Steinberg; Polo Sujov; Eedy Mezer; Ada Tamir; Imad R Makhoul
Journal:  Acta Paediatr       Date:  2008-03       Impact factor: 2.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.